DDInter1943 DDInter899
In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label].
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Vitamin E {u} (Compound) resembles {v} (Compound) Phylloquinone
Vitamin E {u} (Compound) binds {v} (Gene) NR1I2
Vitamin E {u} (Compound) upregulates {v} (Gene) CDK6
Vitamin E {u} (Compound) downregulates {v} (Gene) PTPRO
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mogamulizumab
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Infliximab
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mechlorethamine
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Vitamin E (Compound) resembles Phylloquinone (Compound)
Vitamin E (Compound) binds NR1I2 (Gene)
Vitamin E (Compound) upregulates CDK6 (Gene)
Vitamin E (Compound) downregulates PTPRO (Gene)
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Infliximab
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide